Core Insights - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases [4] - The company will present at the Cantor Fitzgerald 2025 Annual Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference [1][2] - Pociredir, Fulcrum's lead clinical program, aims to treat sickle cell disease (SCD) by increasing fetal hemoglobin (HbF) levels [4][5] Company Overview - Fulcrum Therapeutics specializes in small molecules targeting rare diseases with high unmet medical needs [4] - The company utilizes proprietary technology to identify drug targets that modulate gene expression [4] Product Details - Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) [5] - Initial clinical data showed proof-of-concept with significant increases in HbF levels, indicating potential patient benefits [5] - Pociredir has received FDA Fast Track designation and Orphan Drug Designation for SCD treatment [5] Sickle Cell Disease Context - Sickle cell disease is caused by a mutation in the HBB gene, leading to inefficient oxygen transport and sickle-shaped red blood cells [6] - Patients with SCD face severe clinical consequences, including anemia, pain, and reduced life expectancy [6] Upcoming Events - Fulcrum management will be available for one-on-one meetings during the conferences [3] - Webcast replay links will be available on Fulcrum Therapeutics Investor Relations' Events and Presentations page after the events [3]